• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Thyroid Cancer - Pipeline Review, H2 2011 - Product Image

Thyroid Cancer - Pipeline Review, H2 2011

  • ID: 1881621
  • August 2011
  • 147 pages
  • Global Markets Direct

Thyroid Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Thyroid Cancer - Pipeline Review, H2 2011', provides an overview of the Thyroid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. 'Thyroid Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thyroid Cancer.
- A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thyroid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Thyroid Cancer
Thyroid Cancer Therapeutics under Development by Companies
Thyroid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Thyroid Cancer Therapeutics - Products under Development by Companies
Thyroid Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Thyroid Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
AstraZeneca PLC
Daiichi Sankyo Company, Ltd
Bio-Path Holdings, Inc.
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
Exelixis, Inc.
Bayer AG
MannKind Corporation
OXiGENE, Inc.
Sareum Holdings plc
Vascular Biogenics Ltd.
Thyroid Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E7080 - Drug Profile
Motesanib - Drug Profile
Pasireotide - Drug Profile
Nexavar - Drug Profile
Axitinib - Drug Profile
Caprelsa - Drug Profile
Caprelsa - Drug Profile
MKC1106-PP - Drug Profile
LBH589 - Drug Profile
Zelboraf - Drug Profile
Polo-Like Kinase 1 - Drug Profile
B-RAF - Drug Profile
Afinitor - Drug Profile
VB-111 - Drug Profile
BP-100-2.01 - Drug Profile
R935788 - Drug Profile
CP-4033 - Drug Profile
Gleevec + Dacarbazine + Xeloda - Drug Profile
Iressa - Drug Profile
BAY 43-9006 - Drug Profile
Celecoxib - Drug Profile
Pazopanib Hydrochloride - Drug Profile
Vorinostat - Drug Profile
FR901228 - Drug Profile
Nexavar - Drug Profile
Thalidomide - Drug Profile
Lithium Carbonate - Drug Profile
XL184 + Rosiglitazone - Drug Profile
Temsirolimus + Sorafenib - Drug Profile
Depakote - Drug Profile
Zactima + Velcade - Drug Profile
Irinotecan Hydrochloride - Drug Profile
Revlimid - Drug Profile
Thalidomide - Drug Profile
Afinitor - Drug Profile
Hydroxyurea + Fluorouracil + Paclitaxel + Filgrastim + Radiation therapy - Drug Profile
Romidepsin - Drug Profile
Recombinant thyrotropin - Drug Profile
pemetrexed + paclitaxel - Drug Profile
Zybrestat + Carboplatin + Paclitaxel - Drug Profile
LBH589 - Drug Profile
RAD001 - Drug Profile
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Taxol - Drug Profile
Valproic Acid - Drug Profile
Aflibercept + Radiation theraphy - Drug Profile
Everolimus + Sorafenib - Drug Profile
Fostamatinib - Drug Profile
Sunitinib - Drug Profile
Sorafenib (nexavar) - Drug Profile
Lithium Carbonate - Drug Profile
BAY 43-9006 - Drug Profile
Thyroid-Stimulating Hormone + Iodine I 131 - Drug Profile
AG-013736 - Drug Profile
Bortezomib - Drug Profile
Combretastatin A4 phosphate - Drug Profile
Rosiglitazone Maleate - Drug Profile
Paclitaxel + Pazopanib + Radiation Therapy - Drug Profile
Cisplatin + Crolibulin - Drug Profile
Sorafenib - Drug Profile
Sutent - Drug Profile
Cediranib Maleate + Lenalidomide - Drug Profile
Pasireotide LAR + Everolimus - Drug Profile
Doxorubicin + Interferon Alpha 2b - Drug Profile
CS-7017 + Paclitaxel - Drug Profile
Avastin + Doxorubicin - Drug Profile
Almita + Paclitaxel - Drug Profile
ET-D5 - Drug Profile
Everolimus + Pasireotide - Drug Profile
Thyroid Cancer Therapeutics – Drug Profile Updates
Thyroid Cancer Therapeutics - Discontinued Products
Thyroid Cancer - Featured News
Aug 01, 2011: AstraZeneca Announces Trade Name CAPRELSA For Vandetanib
Jun 06, 2011: OXiGENE's ZYBRESTAT Results Suggest Improvement In Overall Survival In Phase II/III Study In Anaplastic Thyroid Cancer
Jun 02, 2011: Eisai Announces Encouraging Preliminary Results From Phase II study Of Lenvatinib
Jun 02, 2011: Plexxikon Announces New Trial For Vemurafenib In Thyroid Cancer
May 23, 2011: Exelixis Announces Publication Of Phase I Clinical Trial Of Cabozantinib In Journal Of Clinical Oncology
May 23, 2011: VBL Therapeutics To Present Updated Clinical Results For VB-111 At 2011 ASCO Annual Meeting
May 18, 2011: OXiGENE Announces Clinical Data From FACT and FALCON Studies To Be Presented At ASCO
Apr 07, 2011: FDA approves orphan drug vandetanib
Apr 06, 2011: AstraZeneca Receives FDA Approval For Vandetanib For Advanced Medullary Thyroid Cancer
Mar 21, 2011: OXiGENE Receives Meeting Minutes From FDA Type C Meeting On ZYBRESTAT Anaplastic Thyroid Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Thyroid Cancer, H2 2011
Products under Development for Thyroid Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Daiichi Sankyo Company, Ltd, 2011
Bio-Path Holdings, Inc., 2011
Novartis AG, 2011
Eisai Co., Ltd., 2011
Pfizer Inc., 2011
Exelixis, Inc., 2011
Bayer AG, 2011
MannKind Corporation, 2011
OXiGENE, Inc., 2011
Sareum Holdings plc, 2011
Vascular Biogenics Ltd., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Thyroid Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Thyroid Cancer, H2 2011
Products under Development for Thyroid Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos